If I was to invest in another biotech something along the lines of MAP would be it. The enteric system is the future in healthcare. Given COVID, lockdowns and stress, prevalence in stress related conditions have increased like IBS. I believe MAP has a drug in phase 1 for IBS?
There is definite potential here. They are in the correct area for the future of healthcare as the enteric system is still a big unknown and lots of conditions do not have medicines that are effective.
Brought a parcel today.
If I was to invest in another biotech something along the lines...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.77M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 105047 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 86666 | 2 |
View Market Depth
| Last trade - 16.12pm 02/07/2024 (20 minute delay) ? |
| MAP (ASX) Chart |
Day chart unavailable